family with sequence similarity 78 member BGenealiases: []
Q-omics provides the consensus-scored FAM78B profile across patient tissues and cancer cell-line models. FAM78B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM78B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, FAM78B RNA expression shows 16,644 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where FAM78B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM78B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM78B survival associations across molecular data types. FAM78B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM78B RNA expression–survival associations across cancer types. High FAM78B expression shows unfavorable associations in KIRC, KIRP, LGG and STAD, but favorable associations in ESCA and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM78B RNA expression.
This table summarizes FAM78B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM78B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM78B shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRC, LIHC, LUAD and KIRP. The KIRC box plot shows higher FAM78B RNA expression in tumor versus normal tissue (log2 FC = +1.069, t-test p < 0.001).
This table shows molecular features associated with FAM78B in patient tissues and cancer cell lines. In patient samples, FAM78B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM78B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
